Chiesi is recertified as a B Corp and sets new tougher objectives for action by 2025
22 Settembre 2022
Chiesi Group brings together experts to discuss care for respiratory patients and presents a new treatment option for COPD at ERS Congress
05 Settembre 2022
Chiesi announces the departure of Ugo Di Francesco as CEO of the Group
31 Agosto 2022
First carbon minimal pMDI is on track with the goal to benefit patients and planet
27 Luglio 2022
Chiesi tracks actions taken for a healthier, more sustainable future
14 Luglio 2022
Chiesi acquires pioneering therapeutic monoclonal antibodies portfolio against EMAP II as potential treatment for PAH
02 Maggio 2022
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Topline Results from the 24-Month Phase III BALANCE Clinical Trial of PRX-102 for the Treatment of Fabry Disease
07 Aprile 2022
Chiesi Group continues to grow
31 Marzo 2022
Koura opens world’s first HFA 152a medical propellant production facility
30 Marzo 2022
Solidarity actions to support the people affected by the war
